AGP Picks
View all

Tepezza market forecast points to growth through 2035

Nov. 12, 2026
Tepezza market forecast points to growth through 2035
By AI, Created 17:15 UTC, Nov 12, 2026, AGP -

The Business Research Company says the Tepezza market is expanding as thyroid eye disease diagnoses rise, infusion access broadens and interest grows in targeted autoimmune therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest in the years ahead.

Why it matters: - Tepezza is tied to thyroid eye disease, a rare autoimmune condition that can cause inflammation, swelling and vision problems around the eyes. - Rising diagnosis rates and broader use of targeted biologics could expand the patient pool and support demand for specialty infusion treatments. - The market outlook matters to drugmakers, infusion providers and investors tracking rare-disease therapies.

What happened: - The Business Research Company published a Tepezza market report on Nov. 12, 2026. - The report covers market size, trends and a global forecast for 2026-2035. - The company describes Tepezza as a prescription drug containing teprotumumab-trbw, a monoclonal antibody that blocks insulin-like growth factor-1 receptor, or IGF-1R. - The report says North America was the largest regional market in 2025.

The details: - Historical growth was linked to better detection of thyroid eye disease, progress in monoclonal antibody technology, growth in specialty infusion centers and greater awareness of autoimmune eye disorders. - Improved clinical trial results for biologic therapies also supported market growth. - Future demand is expected to rise on the back of increased need for targeted autoimmune treatments, a growing pipeline of biologic drugs, higher investment in rare diseases, personalized ophthalmology care and wider acceptance of outpatient infusion services. - The report flags rising use of IGF-1R-targeted therapies, broader adoption of monoclonal antibodies for autoimmune diseases, more disease-specific biologics, expansion of infusion-based specialty medications and improved patient monitoring during treatment as key trends. - The report says Tepezza treats thyroid eye disease, an autoimmune disorder that affects the muscles and tissues around the eyes. - Tepezza aims to reduce disease symptoms by targeting IGF-1R. - The report also lists Asia-Pacific, Western Europe, Eastern Europe, South America, and the Middle East and Africa as key markets. - The company added expanded strategic intelligence to its 2026 reports, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.

Between the lines: - The market story is not just about one drug. It reflects a broader shift toward precision biologics in autoimmune care. - Better diagnostics can create a larger treated population even when the underlying disease remains rare. - North America’s lead suggests current adoption is strongest where specialty care access is deepest, while Asia-Pacific’s expected growth points to room for broader regional uptake. - The report cites higher thyroid disease incidence as a demand driver, including an estimate from Cancer Research United Kingdom of about 6,600 new thyroid cancer cases annually between 2038 and 2040 and a 27% rise in incidence rates from roughly 7.3 to 9.2 cases per 100,000 people between 2024-2026 and 2038-2040.

What's next: - Asia-Pacific is expected to post substantial growth as healthcare investment rises and awareness of autoimmune conditions expands. - The report indicates continued momentum for infusion-based specialty medications and disease-specific biologics through the rest of the decade. - The company is steering buyers toward its full report and a free sample for deeper market sizing and competitive analysis.

The bottom line: - Tepezza’s market outlook is being lifted by better diagnosis, more biologic innovation and stronger specialty-care access, with North America leading now and Asia-Pacific positioned for faster growth.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Post Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.